Copyright
©The Author(s) 2015.
World J Hepatol. Aug 28, 2015; 7(18): 2177-2183
Published online Aug 28, 2015. doi: 10.4254/wjh.v7.i18.2177
Published online Aug 28, 2015. doi: 10.4254/wjh.v7.i18.2177
Table 3 Main adverse events in 40 patients with available follow-up
| Rash | 10 (25%) |
| Anemia Hb < 13 g/dL (men), < 12 g/dL (women) | 39 (98%) |
| Severe anemia (< 9 g/dL or decrease > 3 g/dL) | 35 (88%) |
| Ribavirin dose decreased | 23 (58%) |
| EPO administration | 23 (58%) |
| Blood transfusion | 2 (5%) |
- Citation: Naqvi A, Giordanengo V, Dunais B, de Salvador-Guillouet F, Perbost I, Durant J, Pugliese P, Joulié A, Roger PM, Rosenthal E. Virological response and resistance mutations to NS3/4A inhibitors in hepatitis C virus-human immunodeficiency virus coinfection. World J Hepatol 2015; 7(18): 2177-2183
- URL: https://www.wjgnet.com/1948-5182/full/v7/i18/2177.htm
- DOI: https://dx.doi.org/10.4254/wjh.v7.i18.2177